Interestingly, runcaciguat and BI 703704 demonstrated in these four different preclinical CKD models a more pronounced reduction of proteinuria in higher, blood pressure lowering dose-regimens, suggesting that there might be also blood pressure-dependent beneficial effects of sGC activators in CKD. This evidence concerns the gene SGCB and chronic kidney disease.